Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
| ▸ | TSPO | P30536 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27899787 | 0.85 | MEN1 (0.50) | MEN1TSHRKMT2ACNR2LMNA | |
| SCHEMBL5851593 | 0.83 | HDAC6 (0.57) | MEN1TSHRKMT2ACNR2EPHX2 | |
| SCHEMBL5849609 | 0.82 | CNR2 (0.40) | TSHRCNR2TP53ALDH1A1 | |
| SCHEMBL5849866 | 0.82 | CNR2 (0.66) | MEN1TSHRKMT2ACNR2TSPO | |
| SCHEMBL28375953 | 0.80 | CNR2 (0.49) | MEN1TSHRKMT2ACNR2EPHX2 | |
| SCHEMBL27917520 | 0.80 | CNR2 (0.48) | MEN1TSHRKMT2ACNR2TSPO | |
| SCHEMBL2215683 | 0.77 | CYP19A1 (0.57) | MEN1KMT2ACNR2SMN1; SMN2KDM4E | |
| SCHEMBL4798568 | 0.76 | THRB (0.39) | — | |
| SCHEMBL27979857 | 0.76 | TSHR (0.51) | MEN1TSHRKMT2ALMNAEPHX2 | |
| SCHEMBL2950609 | 0.76 | MAOB (0.51) | TSHRLMNAEPHX2SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001912-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | claimed |
| US-7138408-B2 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060122211-A1 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| US-7001912-B2 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122211-A1 | HIV integrase inhibitors, pharmaceutical compositions and methods for their use | POLB, POLA1, TYMP | MEN1 4206/4885TSHR 4820/4885KMT2A 835/4885 |
| US-20050165040-A1 | HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use | POLB, APOBEC3C, IDH3A | MEN1 4112/4885TSHR 4826/4885KMT2A 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.